FDA Initiates Class II Recall for Breckenridge Pharmaceutical's Duloxetine Due to N-nitroso-duloxetine Impurity
Breckenridge Pharmaceutical, Inc. has initiated a Class II recall for 172,263 bottles of Duloxetine Delayed-Release Capsules, USP, 60 mg, distributed nationwide in the U.S. This action stems from Current Good Manufacturing Practice (CGMP) deviations, specifically the presence of N-nitroso-duloxetine impurity exceeding the 12.5ppm safety assessment limit. This event necessitates immediate attention from procurement and regulatory teams.
Critical Recall of Duloxetine by Breckenridge Pharmaceutical Due to N-nitroso-duloxetine Impurity
Breckenridge Pharmaceutical, Inc., a key distributor in Berkeley Heights, NJ, has initiated a Class II recall for its Duloxetine Delayed-Release Capsules, USP, 60 mg, impacting the U.S. nationwide market. This significant regulatory action, identified as recall number D-0100-2026, commenced on October 9, 2025, and remains ongoing. The core issue driving this recall is a Current Good Manufacturing Practice (CGMP) deviation, specifically the detection of N-nitroso-duloxetine impurity at levels exceeding the established safety assessment limit of 12.5 parts per million (ppm). This directly impacts product quality and patient safety, demanding immediate attention from procurement and regulatory affairs teams. The affected product, identified by application number ANDA203088, includes two specific lots: 90-count bottles (Lot # 240721C, Exp. 02/28/2027, NDC: 51991-748-90) and 1000-count bottles (Lot #230286C, Exp. 02/28/2026, NDC: 51991-748-10). A total of 172,263 bottles of Duloxetine Delayed-Release Capsules, USP, 60 mg, manufactured by Towa Pharmaceutical Europe, S.L. in Martorelles, Spain, are subject to this recall. For procurement directors, this means an immediate disruption in the supply of this specific generic antidepressant, necessitating rapid assessment of inventory and alternative sourcing strategies to maintain continuity for downstream formulators and patients.
Commercial Repercussions and Supply Chain Vulnerabilities for U.S. Duloxetine Market
The recall of 172,263 bottles of Duloxetine Delayed-Release Capsules, USP, 60 mg, distributed U.S. nationwide by Breckenridge Pharmaceutical, Inc., presents immediate commercial and supply chain challenges. For supply chain VPs, this event signals a critical vulnerability, particularly for those relying on Breckenridge as a primary or secondary supplier for generic Duloxetine. The Class II classification, indicating that the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote, still mandates prompt removal from the market. This impacts not only the immediate availability of the drug but also introduces uncertainty regarding future supply from Breckenridge for this specific ANDA. Procurement directors must quantify their exposure to Breckenridge's Duloxetine (ANDA203088) and understand the lead times required to qualify new suppliers or increase orders from existing ones. The involvement of Towa Pharmaceutical Europe, S.L. as the manufacturer also highlights the complexities of global pharmaceutical supply chains, where manufacturing quality issues abroad can directly impact U.S. market availability. Business development executives should assess how this recall might shift market dynamics for other Duloxetine generic manufacturers, potentially opening opportunities for competitors with robust quality systems and available capacity.
Heightened Regulatory Scrutiny on Nitrosamine Impurities and CGMP Compliance
This recall of Duloxetine due to N-nitroso-duloxetine impurity underscores the FDA's intensified focus on nitrosamine contamination across the pharmaceutical industry. While N-nitroso-duloxetine is a specific impurity, it falls within the broader category of nitrosamines, which have been a major regulatory concern since 2018. Regulatory affairs heads must recognize that this event signals a continued expectation from the FDA for pharmaceutical manufacturers and distributors to implement stringent Current Good Manufacturing Practice (CGMP) controls to prevent and mitigate such impurities. The presence of N-nitroso-duloxetine above the 12.5ppm safety limit indicates a failure in robust quality control and process validation at the manufacturing stage by Towa Pharmaceutical Europe, S.L. Companies are expected to conduct comprehensive risk assessments for all drug products, identify potential sources of nitrosamines, and implement appropriate control strategies, including analytical testing and process modifications. This incident serves as a clear reminder that regulatory bodies will not hesitate to initiate recalls for products failing to meet these evolving impurity standards. Proactive engagement with contract manufacturers and raw material suppliers to ensure their compliance with updated nitrosamine guidelines is paramount to avoid similar costly and reputation-damaging recalls.
Proactive Risk Mitigation for Duloxetine Sourcing: Diversification and Due Diligence
For procurement directors and supply chain VPs, this Class II recall of Breckenridge Pharmaceutical's Duloxetine necessitates an immediate re-evaluation of sourcing strategies for this critical antidepressant. Given the U.S. nationwide distribution impact of 172,263 affected bottles, reliance on a single supplier or a limited number of manufacturers for generic Duloxetine (such as Towa Pharmaceutical Europe, S.L.) carries substantial risk. Companies should prioritize diversifying their supplier base to mitigate future disruptions from similar CGMP deviations or impurity issues. This involves identifying and qualifying alternative manufacturers with established track records of robust quality systems and a history of compliance with FDA regulations. The qualification process, which can be lengthy and resource-intensive, must include thorough audits of manufacturing facilities, detailed review of quality management systems, and verification of impurity control strategies, particularly concerning nitrosamines. Business development executives should consider strategic partnerships that enhance supply chain resilience. Investing in comprehensive due diligence for all suppliers, including contract manufacturing organizations (CMOs) and active pharmaceutical ingredient (API) providers, is no longer merely a best practice but a commercial imperative to safeguard product availability and market share.
Long-Term Implications for Breckenridge and Towa Pharmaceutical Europe's Regulatory Standing
The 'Ongoing' status of this Class II recall for Duloxetine Delayed-Release Capsules, USP, 60 mg, signals continued regulatory scrutiny for both Breckenridge Pharmaceutical, Inc. as the distributor and Towa Pharmaceutical Europe, S.L. as the manufacturer. While the immediate action is a firm-initiated voluntary recall, the underlying CGMP deviations and impurity issues could lead to further FDA actions, including potential Warning Letters or import alerts if comprehensive and timely remediation is not demonstrated. Regulatory affairs heads at both companies must now focus on developing and implementing a robust corrective and preventive action (CAPA) plan. This plan must thoroughly investigate the root cause of the N-nitroso-duloxetine impurity exceeding 12.5ppm, implement necessary process changes at Towa Pharmaceutical Europe, S.L.'s facility in Spain, and ensure enhanced quality control measures. For Breckenridge, ensuring the quality of products from its manufacturing partners is crucial for maintaining its reputation and market access in the U.S. Failure to adequately address these CGMP deviations could impact future product approvals and market opportunities, creating long-term commercial disadvantages. This event serves as a critical reminder that regulatory compliance is a continuous process requiring vigilant oversight throughout the entire product lifecycle and supply chain.